Deutsche Bank AG Acquires 22,412 Shares of Blueprint Medicines Co. (NASDAQ:BPMC)

Deutsche Bank AG raised its stake in shares of Blueprint Medicines Co. (NASDAQ:BPMC - Free Report) by 9.4% during the fourth quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 261,363 shares of the biotechnology company's stock after buying an additional 22,412 shares during the quarter. Deutsche Bank AG owned about 0.41% of Blueprint Medicines worth $22,796,000 at the end of the most recent reporting period.

Other hedge funds also recently bought and sold shares of the company. R Squared Ltd acquired a new position in Blueprint Medicines in the 4th quarter valued at about $51,000. Headlands Technologies LLC acquired a new stake in Blueprint Medicines during the fourth quarter worth approximately $65,000. Thematics Asset Management purchased a new stake in Blueprint Medicines in the 4th quarter worth approximately $72,000. Covestor Ltd lifted its stake in shares of Blueprint Medicines by 62.7% during the 4th quarter. Covestor Ltd now owns 973 shares of the biotechnology company's stock worth $85,000 after purchasing an additional 375 shares during the period. Finally, Asset Management One Co. Ltd. acquired a new stake in shares of Blueprint Medicines during the fourth quarter worth $88,000.

Blueprint Medicines Stock Performance

NASDAQ:BPMC traded down $0.39 during midday trading on Tuesday, reaching $100.84. 44,570 shares of the company traded hands, compared to its average volume of 1,002,381. The company has a debt-to-equity ratio of 1.15, a current ratio of 2.85 and a quick ratio of 2.80. The firm has a market capitalization of $6.51 billion, a price-to-earnings ratio of -93.36 and a beta of 0.83. Blueprint Medicines Co. has a twelve month low of $73.04 and a twelve month high of $121.90. The company has a fifty day moving average price of $89.87 and a 200 day moving average price of $94.47.

Blueprint Medicines (NASDAQ:BPMC - Get Free Report) last released its earnings results on Thursday, May 1st. The biotechnology company reported ($0.74) earnings per share for the quarter, missing analysts' consensus estimates of ($0.42) by ($0.32). Blueprint Medicines had a negative return on equity of 77.49% and a negative net margin of 13.19%. The firm had revenue of $149.41 million during the quarter, compared to analyst estimates of $158.31 million. During the same quarter last year, the company earned $1.40 earnings per share. The business's revenue for the quarter was up 55.5% on a year-over-year basis. On average, analysts expect that Blueprint Medicines Co. will post -1.28 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

Several analysts have commented on the company. JPMorgan Chase & Co. lifted their price target on Blueprint Medicines from $126.00 to $129.00 and gave the company an "overweight" rating in a report on Tuesday, February 4th. Wolfe Research initiated coverage on shares of Blueprint Medicines in a research note on Tuesday, March 18th. They set an "outperform" rating for the company. StockNews.com upgraded Blueprint Medicines from a "sell" rating to a "hold" rating in a report on Friday, May 2nd. HC Wainwright restated a "buy" rating and issued a $135.00 price objective on shares of Blueprint Medicines in a report on Friday, May 2nd. Finally, JMP Securities reiterated a "market outperform" rating and set a $125.00 target price on shares of Blueprint Medicines in a report on Friday, February 14th. Five research analysts have rated the stock with a hold rating, thirteen have given a buy rating and one has issued a strong buy rating to the company. According to data from MarketBeat, the company presently has an average rating of "Moderate Buy" and a consensus target price of $126.56.

Insider Transactions at Blueprint Medicines

In related news, insider Ariel Hurley sold 3,203 shares of Blueprint Medicines stock in a transaction dated Monday, March 3rd. The stock was sold at an average price of $92.62, for a total transaction of $296,661.86. Following the sale, the insider now directly owns 18,270 shares of the company's stock, valued at $1,692,167.40. This trade represents a 14.92% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, COO Christina Rossi sold 2,274 shares of the company's stock in a transaction that occurred on Monday, May 5th. The shares were sold at an average price of $101.75, for a total value of $231,379.50. Following the completion of the transaction, the chief operating officer now directly owns 66,992 shares of the company's stock, valued at approximately $6,816,436. This trade represents a 3.28% decrease in their position. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 10,503 shares of company stock valued at $1,027,931. 4.21% of the stock is owned by insiders.

About Blueprint Medicines

Blueprint Medicines Corporation, a precision therapy company, develops medicines for genomically defined cancers and blood disorders in the United States and internationally. The company is developing AYVAKIT for the treatment of systemic mastocytosis (SM) and gastrointestinal stromal tumors; BLU-263, an orally available, potent, and KIT inhibitor for the treatment of indolent SM, and other mast cell disorders.